|Videos|September 4, 2020

The Older Pediatric COVID-19 Problem

At a time when schools and college campuses have reopened, an expert discusses adolescents' trends in spreading COVID-19 more easily, and the lack of testing available to them.

An asymptomatic pediatric coronavirus 2019 (COVID-19) rate of just 1% is enough to assure that modern testing protocol could never practically resolve the spread of undetectable cases.

But that doesn’t make the current US COVID-19 testing strategy any more appropriate.

In the final segment of an interview with Contagion®, Dylan K. Chan, MD, of the University of California San Francisco (UCSF) Division of Pediatric Otolaryngology, Department of Otolaryngology—Head and Neck Surgery, shared perspective on what his team’s Pediatric COVID-19 Risk Assessment Tool means for younger patient spread in the coming months.

As he explained, small prevalence rates from 1-3% create an inevitability of “super spread” events in classrooms, get-togethers, and other gatherings.

“I don’t think it’s a surprise at all, knowing what we know about these numbers,” he said.

Chan also explained what these findings, coupled with national guidance to refrain from asymptomatic-risk testing due to limited resources, spell for future management of COVID-19.

He’s in agreement that, in current circumstances of testing scarcity, greater-risk persons need to be prioritized—and that puts children at the end of the line.

“That’s not an ideal situation, and we’re never going to get things under control as long as we’re in that situation,” he said.


Related to this article

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Measles Update: October 16, 2026
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.